HCM HUTCHMED (China) Ltd
Pharmaceutical Preparations · Nasdaq · SEC CIK 1648257
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-13.0%
TTM net income YoY1,111.0%
TTM EPS YoY1,200.0%
Revenue 3-yr CAGR8.8%
Net income 3-yr CAGR—
Margins
Gross margin38.7%
Operating margin-7.1%
Net margin83.3%
FCF margin-14.4%
EBITDA margin-4.7%
Returns
ROE45.7%
ROA30.2%
ROIC (approx.)-3.5%
Asset turnover0.36x
Leverage & solvency
Liabilities / assets28.6%
Debt / equity0.08x
Current ratio4.96x
Interest coverage-13.67x
Cash quality & payout
Operating cash flow / net income-0.14x
Accruals ratio34.5%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2019Q4*2019-12-31 | 2019Q3*2019-09-30 | 2019Q2*2019-06-30 | 2019Q12019-03-31 | 2018Q4*2018-12-31 | 2018Q3*2018-09-30 | 2018Q2*2018-06-30 | 2018Q12018-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $53.34M | $49.35M | $50.03M | $52.17M | $53.11M | $58.81M | $49.85M | $52.34M |
| R&D expense | $37.45M | $31.45M | $36.01M | $33.28M | $25.43M | $28.68M | $31.39M | $28.66M |
| SG&A expense | $8.92M | $11.46M | $8.63M | $10.20M | $8.94M | $7.42M | $7.53M | $7.02M |
| Operating income | -$38.43M | -$35.94M | -$35.96M | -$36.05M | -$24.17M | -$14.79M | -$28.66M | -$25.02M |
| Interest expense | $259,000 | $83,000 | $428,000 | $260,000 | $281,000 | $284,000 | $238,000 | $206,000 |
| Pretax income | -$38.47M | -$34.34M | -$33.39M | -$34.91M | -$23.06M | -$13.10M | -$26.62M | -$23.87M |
| Income tax | $715,000 | $97,000 | $1.15M | $1.31M | $969,000 | $315,000 | $1.11M | $1.56M |
| Net income | -$29.56M | -$31.09M | -$25.48M | -$19.89M | -$16.54M | -$25.58M | -$20.96M | -$11.73M |
| EBITDA | -$37.13M | -$34.71M | -$34.76M | -$34.84M | -$23.14M | -$13.91M | -$27.81M | -$24.19M |
| EPS (basic) | — | — | — | -0.03 | — | — | — | -0.02 |
| EPS (diluted) | — | — | — | -0.03 | — | — | — | -0.02 |
| Weighted avg. shares (diluted) | — | — | — | 665.47M | — | — | — | 663.84M |
| Banking | ||||||||
| Deposits | $1.78M | $1.27M | $1.30M | $1.90M | $1.23M | — | $1.39M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $121.16M | $97.08M | $83.36M | $91.69M | $86.04M | $115.59M | $75.33M | $78.10M |
| Short-term investments | $96.01M | $104.49M | $153.93M | $180.17M | $214.91M | — | $247.16M | — |
| Receivables | $41.41M | $40.33M | $42.76M | $42.27M | $40.18M | — | $44.42M | — |
| Inventory | $16.21M | $15.65M | $14.22M | $17.61M | $12.31M | — | $9.79M | — |
| Current assets | $317.02M | $277.08M | $309.50M | $349.99M | $370.54M | — | $394.68M | — |
| PP&E, net | $20.86M | $18.53M | $17.67M | $17.04M | $16.62M | — | $14.42M | — |
| Goodwill | $3.11M | $3.09M | $3.19M | $3.26M | $3.19M | — | $3.36M | — |
| Intangibles | $275,000 | $288,000 | $315,000 | $340,000 | $347,000 | — | $403,000 | — |
| Total assets | $465.12M | $454.09M | $495.21M | $539.30M | $532.12M | — | $577.94M | — |
| Current liabilities | $113.10M | $105.34M | $110.61M | $101.33M | $85.48M | — | $84.58M | — |
| Long-term debt | $26.82M | $0 | $0 | $26.76M | $26.74M | — | $26.69M | — |
| Total debt | $26.82M | $0 | $0 | $26.76M | $26.74M | — | $26.69M | — |
| Total liabilities | $152.22M | $116.31M | $122.18M | $138.94M | $119.86M | — | $120.10M | — |
| Shareholders' equity | $288.01M | $313.52M | $347.89M | $375.77M | $389.00M | $424.70M | $431.73M | $478.40M |
| Net debt | -$94.34M | -$97.08M | -$83.36M | -$64.93M | -$59.30M | — | -$48.64M | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$17.39M | -$33.48M | -$1.12M | -$28.92M | -$13.94M | -$315,000 | $12.24M | -$30.84M |
| Capital expenditure | $2.95M | $1.77M | $2.49M | $1.36M | $2.93M | $1.35M | $761,000 | $1.32M |
| Free cash flow | -$20.34M | -$35.25M | -$3.61M | -$30.28M | -$16.87M | -$1.67M | $11.48M | -$32.16M |
| Investing cash flow | $14.22M | $47.67M | $23.76M | $33.38M | -$15.26M | $43.22M | -$11.92M | $27.71M |
| Financing cash flow | $26.90M | $1.12M | -$29.17M | -$346,000 | -$413,000 | $24,000 | -$2.61M | -$5.23M |
| Depreciation & amortization | $1.31M | $1.23M | $1.20M | $1.21M | $1.03M | $874,000 | $854,000 | $834,000 |
| Share buybacks | $0 | $0 | $0 | $346,000 | $0 | $0 | $0 | $5.45M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.